🔗 Share this article Patients Discontinuing Weight-Loss Injections Regain Pounds Far More Rapidly Than People Using Diet and Exercise Weight management involves ongoing approaches. Fresh analysis reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop conventional diet and exercise plans. Research printed in a prominent health publication shows that while overweight people frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals buying these medications should be aware of the potential of rapid weight regain when the medication ends," stated expert Dr. Susan Jebb. That rate of recovery suggests a reversion to starting mass within about a year and a half. Weighing Treatments The analysis, which looked at dozens of trials involving over 9,000 of participants, compared the results of these new drugs with other pills. The team note that individuals who lose weight through lifestyle changes alone usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish. Understanding the Rapid Regain Nutrition scientists propose the mode of action of the drugs is key to understanding the amplified regain. These medications copy a natural hormone called glucagon-like peptide-1, which moderates hunger. "Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert. "Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating far more likely." A Lifelong Issue? Medical guidelines advise the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications. A number of clinicians contend that, due to the likelihood of weight regain, the therapy might need to be long-term. This opinion is reinforced by pharmaceutical companies, who state that the findings "highlight the persistent nature of excess weight," comparing it to managing conditions like diabetes. User Experiences Users who have discontinued the jabs explain a sudden return of hunger. "I experienced something activating and I was suddenly starving," recalled one woman. This challenge is worsened if patients have not adopted sustainable lifestyle or habit modifications during treatment. Widespread Interest Figures suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial. Adoption is greater among women compared to men. The 40s and 50s demographic shows the highest usage rates. Many obtain the medications through private healthcare rather than the NHS. Finally, clinicians caution that while these medications are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on integrated behavioural support.
Weight management involves ongoing approaches. Fresh analysis reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop conventional diet and exercise plans. Research printed in a prominent health publication shows that while overweight people frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals buying these medications should be aware of the potential of rapid weight regain when the medication ends," stated expert Dr. Susan Jebb. That rate of recovery suggests a reversion to starting mass within about a year and a half. Weighing Treatments The analysis, which looked at dozens of trials involving over 9,000 of participants, compared the results of these new drugs with other pills. The team note that individuals who lose weight through lifestyle changes alone usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish. Understanding the Rapid Regain Nutrition scientists propose the mode of action of the drugs is key to understanding the amplified regain. These medications copy a natural hormone called glucagon-like peptide-1, which moderates hunger. "Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert. "Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating far more likely." A Lifelong Issue? Medical guidelines advise the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications. A number of clinicians contend that, due to the likelihood of weight regain, the therapy might need to be long-term. This opinion is reinforced by pharmaceutical companies, who state that the findings "highlight the persistent nature of excess weight," comparing it to managing conditions like diabetes. User Experiences Users who have discontinued the jabs explain a sudden return of hunger. "I experienced something activating and I was suddenly starving," recalled one woman. This challenge is worsened if patients have not adopted sustainable lifestyle or habit modifications during treatment. Widespread Interest Figures suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial. Adoption is greater among women compared to men. The 40s and 50s demographic shows the highest usage rates. Many obtain the medications through private healthcare rather than the NHS. Finally, clinicians caution that while these medications are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on integrated behavioural support.